 therapy patients metastatic malignant melanoma phase II study Forty-seven patients metastatic malignant melanoma cycles U/kg recombinant IV hours week dose schedule identical previous lymphokine-activated killer LAK cell phase II clinical trial Working Group Patient eligibility criteria clinical management guidelines similar previous trial Forty-six patients assessable response Objective responses patients complete responses CRs partial responses PRs responses lung liver lymph nodes subcutaneous sites median response duration months Toxicity significant patients myocardial infarction patient therapy toxicity response rate single-agent similar combination LAK cells previous trial results single-agent therapy schedule significant antimelanoma activity humans LAK cells peripheral blood little antimelanoma activity dose schedule